Endpoints News

Spyre hits a speed bump		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T Wed Th F

26 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

news

Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial

Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data

Exclusive: Can AI chop clinical trial timelines in half? Faro raises $37M to find out

Aug 27

12:00 pm ET

Same molecule, different paths: Where value goes in cross-border dealmaking in a new era

sponsored by GeneDx

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

ENDPOINTS PHARMA

Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg

FDA approves Jazz's Ziihera in frontline gastric cancer

Amgen, medical centers diverge on potential conflicts in FDA pilot to speed early drug trials

in case you missed it

ARCH and Population Health join China blitz with Haisco deal

Exclusive: Bausch + Lomb plans Phase 3 trial for dry eye drop, despite missing mid-stage goal

News Briefing

J&J’s Imaavy wins label expansion; Two approvals in Japan

More than 18,000 questionable images found in antibody catalogues of 15 companies

Revier leaves stealth mode to develop cardiometabolic drugs

Chemical & Engineering News

Akeso said that its closely-watched PD-1xVEGF bispecific succeeded in a China-only Phase 3 trial in biliary tract cancer. But what does this mean for its partner Summit Therapeutics? Check out our coverage here.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com